FATE THERAPEUTICS INC (FATE) SEC Filings

Fate Therapeutics director Robert S. Epstein received a grant of stock options covering 87,900 shares of common stock. The options have an exercise price of $2.06 per share and expire on June 12, 2036. This award was issued under the company’s Amended and Restated Non-Employee Director Compensation Policy as an annual equity grant for non-employee directors.

The options will vest and become exercisable on the earlier of June 12, 2027 or the date of Fate Therapeutics’ 2027 Annual Meeting of Stockholders, as long as Epstein continues to serve on the board. After this grant, he holds 87,900 options directly.

Fate Therapeutics director Shefali Agarwal received a new stock option grant covering 87,900 shares of common stock. The option has an exercise price of $2.06 per share and expires on June 12, 2036. It will vest and become exercisable on the earlier of June 12, 2027 or the company’s 2027 Annual Meeting of Stockholders, contingent on her continued board service. Following this grant, she holds options on 87,900 shares directly.

FATE Therapeutics director Matt Abernethy received a new stock option grant covering 87,900 shares of common stock. The option has an exercise price of $2.06 per share and expires on June 12, 2036.

The grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides annual equity awards on the date of the Annual Meeting of Stockholders. These options vest and become exercisable on the earlier of June 12, 2027 or the date of the 2027 Annual Meeting, as long as Abernethy continues to serve on the board.

Fate Therapeutics director William H. Rastetter received a grant of stock options covering 87,900 shares of Common Stock. The options have an exercise price of $2.06 per share and expire on June 12, 2036.

The grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides annual equity awards to non-employee directors on the date of the Annual Meeting of Stockholders. These options vest and become exercisable on the earlier of June 12, 2027 or the date of the 2027 Annual Meeting of Stockholders, subject to his continued service on the Board. Following this grant, he holds 87,900 options according to this filing.

Fate Therapeutics director Laura Hamill received a grant of stock options to acquire 175,800 shares of Common Stock. The options have an exercise price of $2.06 per share and expire on June 12, 2036. This grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides equity upon a director’s appointment or election. The options vest in 36 equal monthly installments starting on June 12, 2026 and will be fully vested on June 12, 2029, contingent on Hamill’s continued service on the Board.

FATE Therapeutics Inc. director Laura Hamill has filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The data provided shows no reported transactions or derivative positions, indicating this is an administrative disclosure of her insider status rather than a trading event.

Fate Therapeutics, Inc. reported results of its Annual Meeting of Stockholders held on June 12, 2026. Stockholders approved a third amendment and restatement of the company’s 2022 Stock Option and Incentive Plan, increasing the maximum number of shares available under the plan by an additional 7,000,000 shares.

All three Class I director nominees were elected to serve until the 2029 annual meeting or until successors are elected and qualified. Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved on a non-binding advisory basis the compensation of the named executive officers as described in the company’s proxy statement.

A total of 116,281,693 shares of common stock were entitled to vote as of the record date, and 87,134,422 shares were present or represented by proxy at the meeting, so all proposals received sufficient support to pass.

Fate Therapeutics, Inc. updated its corporate presentation, highlighting progress in its off-the-shelf cell therapy pipeline for autoimmune diseases and cancer. Lead asset FT819, an anti-CD19 CAR T-cell, showed encouraging Phase 1 safety and activity in systemic lupus erythematosus, including outpatient dosing and deep B-cell depletion with less-intensive or no conditioning chemotherapy.

The company plans a potentially registrational Phase 2 FT819-201 trial in lupus nephritis, targeting 53 patients and aiming to start enrollment in 2H 2026 under RMAT and CDRP programs. Next-generation candidate FT836, a MICA/B-targeting CAR T-cell, demonstrated preliminary anti-tumor activity and tolerability in heavily pretreated KRAS wild-type colorectal cancer without conditioning chemotherapy. Fate also introduced FT839 and other engineered products leveraging its iPSC platform and immune-evasion technologies.

Financially, Fate reported about $174.8 million in cash, cash equivalents, and investments as of March 31, 2026, a cash runway into 2028, and roughly 20% lower operating expenses year over year in Q1 2026, reflecting tighter R&D and G&A spending.

Fate Therapeutics officer Cindy Tahl reported an open-market sale of 25,590 shares of common stock at a weighted average price of $1.879 per share. The company states the shares were sold solely to cover tax withholding on the vesting of 50,000 performance-based RSUs granted on July 29, 2024, under a pre-arranged sell-to-cover election rather than at her discretion.

After these tax-related sales, Tahl directly holds 628,155 shares of Fate Therapeutics common stock.